Freeline Therapeutics Holdings PLC reports results for the quarter ended in December - Earnings Summary

Freeline Therapeutics Holdings

31/03/2022 23:09

* Freeline Therapeutics Holdings PLC  FRLN.OQ  reported a
quarterly adjusted loss of 96 cents​​ per share for the quarter
ended in December. The mean expectation of seven analysts for
the quarter was for a loss of 68 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Freeline Therapeutics Holdings PLC's reported EPS for the
quarter was a loss of 96 cents​.
    * The mean earnings estimate of analysts had risen by
about 6.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Freeline Therapeutics Holdings PLC shares had fallen
by 41.9%
this quarter.
    * The company reported a quarterly loss of $34.7 million.
    * Wall Street's median 12-month price target for Freeline
Therapeutics Holdings PLC is $10.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 31 at 10:08 p.m.  ​All
figures in US dollars unless otherwise stated